Edwards Lifesciences (NYSE:EW) had its price target lifted by investment analysts at Cowen from $250.00 to $265.00 in a note issued to investors on Thursday, The Fly reports. The firm currently has a “positive” rating on the medical research company’s stock. Cowen’s target price would suggest a potential upside of 16.11% from the stock’s current price.
EW has been the subject of several other reports. Credit Suisse Group lifted their target price on Edwards Lifesciences from $226.00 to $261.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. BMO Capital Markets lifted their target price on Edwards Lifesciences from $204.00 to $224.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $232.00 target price for the company in a research report on Thursday, July 25th. Citigroup set a $159.00 price objective on Edwards Lifesciences and gave the company a “sell” rating in a report on Friday, July 26th. Finally, Morgan Stanley lifted their price objective on Edwards Lifesciences from $210.00 to $228.00 and gave the company an “overweight” rating in a report on Wednesday, July 24th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $237.89.
NYSE EW opened at $228.23 on Thursday. The company has a quick ratio of 2.48, a current ratio of 3.38 and a debt-to-equity ratio of 0.18. The company has a fifty day moving average of $222.41 and a two-hundred day moving average of $199.73. The firm has a market capitalization of $46.83 billion, a price-to-earnings ratio of 48.56, a PEG ratio of 2.84 and a beta of 0.84. Edwards Lifesciences has a 52 week low of $136.44 and a 52 week high of $238.37.
In other news, VP Donald E. Bobo, Jr. sold 21,000 shares of the business’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $211.92, for a total transaction of $4,450,320.00. Following the sale, the vice president now owns 41,713 shares in the company, valued at $8,839,818.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 7,500 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $225.74, for a total value of $1,693,050.00. Following the sale, the chief financial officer now owns 21,064 shares in the company, valued at approximately $4,754,987.36. The disclosure for this sale can be found here. Insiders sold 137,253 shares of company stock worth $29,736,031 in the last quarter. 1.63% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of the company. Bath Savings Trust Co grew its holdings in shares of Edwards Lifesciences by 7.7% during the 2nd quarter. Bath Savings Trust Co now owns 27,121 shares of the medical research company’s stock worth $5,010,000 after purchasing an additional 1,949 shares during the period. WINTON GROUP Ltd boosted its holdings in Edwards Lifesciences by 41.1% during the 2nd quarter. WINTON GROUP Ltd now owns 5,744 shares of the medical research company’s stock valued at $1,061,000 after acquiring an additional 1,673 shares during the period. RDA Financial Network boosted its holdings in Edwards Lifesciences by 6.9% during the 2nd quarter. RDA Financial Network now owns 4,313 shares of the medical research company’s stock valued at $805,000 after acquiring an additional 280 shares during the period. New England Research & Management Inc. purchased a new position in Edwards Lifesciences during the 2nd quarter valued at about $323,000. Finally, Harbour Capital Advisors LLC boosted its holdings in Edwards Lifesciences by 0.9% during the 2nd quarter. Harbour Capital Advisors LLC now owns 11,085 shares of the medical research company’s stock valued at $2,048,000 after acquiring an additional 98 shares during the period. Institutional investors and hedge funds own 81.75% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
See Also: How Short Selling Works
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.